microRNA-375 inhibits the malignant behaviors of hepatic carcinoma cells by targeting NCAPG2

Dai, Haitao; Wang, Shu-Tong; Chen, Bin; Tang, Keyu; Li, Nan; Wen, Chunyong; Yuan, Wei; Zhang, Guiyuan; Huang, Yonghui; Geng, Zhi-Jun

doi:10.4149/neo_2021_210318n358

Cited by 6 publications

(3 citation statements)

References 26 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The evaluation of miRNA expression among these chemoresistant cell lines demonstrated a positive association with miR-375 expression, which may be one of the first studies to validate this result in a commercially available cell line [ 20 , 21 , 22 ]. Studies of miR-375 among liver cancers have demonstrated that this resistance may function through modulation of Non-SMC Condensin II Complex Subunit G2 (NCAPG2), Interleukin 6 (IL-6) and Transforming growth factor-beta (TGF-β) [ 34 , 35 ]. Additional research studies of osteosarcoma have demonstrated that miR-375 may function through interactions with Autophagy related gene 2B (ATG2B) and Myeloid leukemia cell differentiation protein (Mcl-1) [ 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines

Huni

Cheung²,

Sullivan³

et al. 2023

IJMS

View full text Add to dashboard Cite

Recent advances have suggested that non-coding miRNAs (such as miR-21, miR-27, miR-145, miR-155, miR-365, miR-375 and miR-494) may be involved in multiple aspects of oral cancer chemotherapeutic responsiveness. This study evaluated whether these specific miRNAs are correlated with oral cancer responsiveness to chemotherapies, including Paclitaxel, Cisplatin and Fluorouracil (5FU). Commercially available and well-characterized oral squamous cell carcinoma cell lines (SCC4, SCC9, SCC15, SCC25 and CAL27) revealed differing resistance and chemosensitivity to these agents—with SCC9 and SCC25 demonstrating the most resistance to all chemotherapeutic agents. SCC9 and SCC25 were also the only cell lines that expressed miR-375, and were the only cell lines that did not express miR-27. In addition, the expression of miR-375 was associated with the upregulation of Rearranged L-myc fusion (RLF) and the downregulation of Centriolar protein B (POC1), whereas lack of miR-27 expression was associated with Nucleophosmin 1 (NPM1) expression. These data have revealed important regulatory pathways and mechanisms associated with oral cancer proliferation and resistance that must be explored in future studies of potential therapeutic interventions.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines

Huni

Cheung²,

Sullivan³

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…According to our study, "Hep G2 cells'' began to appear in HCC research after 2000 along with "MircroRNAs'' and it subsequently showed a rapid increase in appearance. Researchers can use Hep G2 cells to manipulate the expression of specific microRNAs, which will enable them to study the potential of microRNAs as diagnostic and therapeutic targets for HCC (30)(31)(32)(33).…”

Section: Discussionmentioning

confidence: 99%

A systematic review of progress on hepatocellular carcinoma research over the past 30 years: a machine-learning-based bibliometric analysis

Lee,

Hwang,

Sohn

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionResearch on hepatocellular carcinoma (HCC) has grown significantly, and researchers cannot access the vast amount of literature. This study aimed to explore the research progress in studying HCC over the past 30 years using a machine learning-based bibliometric analysis and to suggest future research directions.MethodsComprehensive research was conducted between 1991 and 2020 in the public version of the PubMed database using the MeSH term “hepatocellular carcinoma.” The complete records of the collected results were downloaded in Extensible Markup Language format, and the metadata of each publication, such as the publication year, the type of research, the corresponding author’s country, the title, the abstract, and the MeSH terms, were analyzed. We adopted a latent Dirichlet allocation topic modeling method on the Python platform to analyze the research topics of the scientific publications.ResultsIn the last 30 years, there has been significant and constant growth in the annual publications about HCC (annual percentage growth rate: 7.34%). Overall, 62,856 articles related to HCC from the past 30 years were searched and finally included in this study. Among the diagnosis-related terms, “Liver Cirrhosis” was the most studied. However, in the 2010s, “Biomarkers, Tumor” began to outpace “Liver Cirrhosis.” Regarding the treatment-related MeSH terms, “Hepatectomy” was the most studied; however, recent studies related to “Antineoplastic Agents” showed a tendency to supersede hepatectomy. Regarding basic research, the study of “Cell Lines, Tumors,’’ appeared after 2000 and has been the most studied among these terms.ConclusionThis was the first machine learning-based bibliometric study to analyze more than 60,000 publications about HCC over the past 30 years. Despite significant efforts in analyzing the literature on basic research, its connection with the clinical field is still lacking. Therefore, more efforts are needed to convert and apply basic research results to clinical treatment. Additionally, it was found that microRNAs have potential as diagnostic and therapeutic targets for HCC.

show abstract

“…Multiple profiling studies have highlighted that miRNA expression is substantially different between human tumour and non-tumour livers. miRNAs that normally exert tumour-suppressive effects by repressing oncogenes are recurrently down-regulated in HCC, such as miR-15a/16-1, miR-122, miR-139 miR-192, miR-199a/b-3p and miR-275 [26][27][28][29][30][31][32][33][34]. On the other hand, the miRNAs known as 'oncomiRs' promote oncogenesis by negatively regulating important tumour-suppressive protein-coding genes, and they are aberrantly increased in HCC.…”

Section: Hepatic and Circulating Mirnas And Hccmentioning

confidence: 99%

Epigenetic remodelling in human hepatocellular carcinoma

Braghini

Romito

et al. 2022

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, being the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related death. As other heterogeneous solid tumours, HCC results from a unique synergistic combination of genetic alterations mixed with epigenetic modifications.In HCC the patterns and frequencies of somatic variations change depending on the nearby chromatin. On the other hand, epigenetic alterations often induce genomic instability prone to mutations. Epigenetics refers to heritable states of gene expression without alteration to the DNA sequence itself and, unlike genetic changes, the epigenetic modifications are reversible and affect gene expression more extensively than genetic changes. Thus, studies of epigenetic regulation and the involved molecular machinery are greatly contributing to the understanding of the mechanisms that underline HCC onset and heterogeneity. Moreover, this knowledge may help to identify biomarkers for HCC diagnosis and prognosis, as well as future new targets for more efficacious therapeutic approaches.In this comprehensive review we will discuss the state-of-the-art knowledge about the epigenetic landscape in hepatocarcinogenesis, including evidence on the diagnostic and prognostic role of non-coding RNAs, modifications occurring at the chromatin level, and their role in the era of precision medicine.Apart from other better-known risk factors that predispose to the development of HCC, characterization of the epigenetic remodelling that occurs during hepatocarcinogenesis could open the way to the identification of personalized biomarkers. It may also enable a more accurate diagnosis and stratification of patients, and the discovery of new targets for more efficient therapeutic approaches.

show abstract

microRNA-375 inhibits the malignant behaviors of hepatic carcinoma cells by targeting NCAPG2

Cited by 6 publications

References 26 publications

Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines

Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines

A systematic review of progress on hepatocellular carcinoma research over the past 30 years: a machine-learning-based bibliometric analysis

Epigenetic remodelling in human hepatocellular carcinoma

Contact Info

Product

Resources

About